assyro - Robuta Search

https://assyro.com/regulatory-intelligence/us/letters/approved/761166-2021-orig1s000otheractionltrs Approval Letter Other 761166 (Jan 1, 2021) | Approval Letter | Assyro This is a Complete Response Letter from the FDA to PharmaEssentia Corporation regarding Biologics License Application (BLA) 761166 for P1101, indicating that... approval letter jan assyro https://assyro.com/use-cases/cro/pharmacovigilance PV/Drug Safety in CRO | Assyro AI AI-powered regulatory tools for pharmacovigilance professionals in contract research organizations. Track global pharmacovigilance regulations and... drug safety pv cro assyro ai https://assyro.com/regulatory-intelligence/us/letters/approved/761315-2025-orig1s000otheractionltrs Approval Letter Other 761315 (Jan 1, 2025) | Approval Letter | Assyro This is a Complete Response Letter from the FDA to Novo Nordisk regarding Biologics License Application (BLA) 761315 for NNC0172-2021 injection. The FDA has... approval letter jan assyro https://assyro.com/use-cases/cro/clinical Clinical in CRO | Assyro AI AI-powered regulatory tools for clinical development professionals in contract research organizations. Track clinical trial regulations across global markets.... clinical cro assyro ai https://assyro.com/glossary/estar eSTAR Definition | Assyro AI FDA's interactive PDF template required for all 510(k) submissions and extended to De Novo classification requests. Learn more about eSTAR in regulatory... estar definition assyro ai https://assyro.com/glossary/first-in-human First-in-Human Study (FIH) - Definition | Assyro AI The first clinical trial in which an investigational product is administered to human subjects, typically as a Phase 1 study. Learn more about FIH in... human study first fih definition assyro https://assyro.com/regulatory-intelligence/us/cfr/title-21/part-120 21 CFR Part 120 | Assyro RegIntel Authoritative 21 CFR Part 120 reference. Navigate part 120. Stay inspection-ready with Assyro regulatory intelligence. cfr part assyro https://assyro.com/use-cases/pharmaceutical/cmc CMC in Pharma | Assyro AI AI-powered regulatory tools for cmc/manufacturing professionals in pharmaceutical companies. Track ICH quality guidelines automatically and get alerts when... cmc pharma assyro ai https://assyro.com/regulatory-intelligence/us/cfr/title-21/part-892 21 CFR Part 892 | Assyro RegIntel Authoritative 21 CFR Part 892 reference. Navigate part 892. Stay inspection-ready with Assyro regulatory intelligence. cfr part assyro https://assyro.com/regulatory-intelligence/us/letters/approved/215064-2024-orig1s000otheractionltrs Approval Letter Other 215064 (Jan 1, 2024) | Approval Letter | Assyro The FDA issued a Complete Response letter for NDA 215064 for Filsuvez (birch triterpenes) gel, indicating that the application cannot be approved in its... approval letter jan assyro https://assyro.com/platform/gap-analysis Regulatory Gap Analysis Software | Assyro Regulatory gap analysis software for readiness scanning, prioritized remediation, owner routing, and submission risk tracking. gap analysis regulatory software assyro https://assyro.com/regulatory-intelligence/us/letters/complete-response/crl-nda216442-20250402 Complete Response Letter NDA 505b1 216442 (Apr 2, 2025) | Complete Response Letter | Assyro The FDA has identified deficiencies in NDA 216442, primarily concerning the robustness of Study 030's primary efficacy endpoint analysis and the statistical... response letter complete nda apr assyro https://assyro.com/regulatory-intelligence/us/letters/complete-response/crl-nda218879-20250103 Complete Response Letter NDA 505b1 218879 (Jan 3, 2025) | Complete Response Letter | Assyro This FDA letter for NDA 218879 outlines deficiencies and requirements for the applicant to address in a resubmission. It details specific instructions for... response letter complete nda jan assyro https://assyro.com/regulatory-intelligence/us/letters/approved/217186orig1s000otheractionltrs Approval Letter Other (Nov 13, 2025) | Approval Letter | Assyro The FDA issued a Complete Response letter for NDA 217186 for Crexont (carbidopa and levodopa) Extended Release Capsules, indicating that the application cannot... approval letter nov assyro https://assyro.com/regulatory-intelligence/us/cfr/title-21/part-701 21 CFR Part 701 | Assyro RegIntel Authoritative 21 CFR Part 701 reference. Navigate part 701. Stay inspection-ready with Assyro regulatory intelligence. cfr part assyro https://assyro.com/regulatory-intelligence/us/cfr/title-21/part-21 21 CFR Part 21 | Assyro RegIntel Authoritative 21 CFR Part 21 reference. Navigate part 21. Stay inspection-ready with Assyro regulatory intelligence. cfr part assyro https://assyro.com/blog/cbec-supplement-fda-guide CBE-0 & CBE-30 Supplements: FDA Filing Guide May 2026 | Assyro AI May 1, 2026 - CBE-0 and CBE-30 supplements allow post-approval changes before full FDA review. Learn filing requirements, timing rules, and risks under 21 CFR 314.70. cbe supplements fda https://assyro.com/blog/paperless-qms-software-guide Paperless QMS Software: FDA Part 11 Guide | Assyro AI Apr 2, 2026 - Paperless QMS software guide covering FDA Part 11, electronic records, audit trails, e-signatures, document control, and inspections. qms software paperless fda part guide https://assyro.com/regulatory-intelligence/us/cfr/title-21/part-203 21 CFR Part 203 | Assyro RegIntel Authoritative 21 CFR Part 203 reference. Navigate part 203. Stay inspection-ready with Assyro regulatory intelligence. cfr part assyro https://assyro.com/glossary/bimo Bioresearch Monitoring (BIMO) - Definition | Assyro AI FDA's program that inspects clinical investigators, sponsors, IRBs, and nonclinical laboratories to verify compliance with applicable reg... bioresearch monitoring bimo definition assyro https://assyro.com/blog/medical-device-qms-software-guide Medical Device QMS Software: FDA QMSR Guide | Assyro AI Mar 30, 2026 - Medical device QMS software guide covering FDA QMSR, ISO 13485, Part 820, CAPA, complaints, audits, and eSTAR readiness. medical device qms software fda qmsr guide assyro https://assyro.com/regulatory-intelligence/us/letters/approved/206089-2019-orig1s000otheractionltrs Approval Letter Other 206089 (Jan 1, 2019) | Approval Letter | Assyro The FDA issued a Complete Response letter for Clarus Therapeutics, Inc.'s New Drug Application (NDA) for testosterone undecanoate (TU) (oral), indicating that... approval letter jan assyro https://assyro.com/regulatory-intelligence/us/letters/complete-response/crl-nda217433-20240715 Complete Response Letter NDA 505b1 217433 (Jul 15, 2024) | Complete Response Letter | Assyro This FDA letter for NDA 217433 outlines deficiencies related to product quality, human factors, prescribing information, carton and container labeling, and... response letter complete nda jul assyro https://assyro.com/regulatory-intelligence/us/letters/approved/212122-2021-orig1s000otheractionltrs Approval Letter Other 212122 (Jan 1, 2021) | Approval Letter | Assyro This letter from the FDA's Center for Drug Evaluation and Research outlines deficiencies in New Drug Application (NDA) 212122 for Breztri Aerosphere and... approval letter jan assyro https://assyro.com/regulatory-intelligence/us/letters/approved/209575-2020-orig1s000otheractionltrs Approval Letter Other 209575 (Jan 1, 2020) | Approval Letter | Assyro This document is a Complete Response letter from the FDA to Lannett Holdings, Inc. regarding their New Drug Application (NDA) 209575 for Cocaine Hydrochloride... approval letter jan assyro https://assyro.com/glossary/qtpp Quality Target Product Profile (QTPP) - Definition | Assyro AI A prospective summary of the quality characteristics a drug product should possess to deliver the intended therapeutic benefit to the pat... product profile quality target definition assyro https://assyro.com/blog/rolling-nda-submission Rolling NDA Submission: Fast Track Strategy May 2026 | Assyro AI May 1, 2026 - Rolling NDA submission guide: eligibility, section sequencing, and FDA communication requirements. Learn how rolling review accelerates approval for expedite... fast track rolling nda submission strategy https://assyro.com/regulatory-intelligence/us/letters/approved/761306-2024-orig1s000otheractionltrs Approval Letter Other 761306 (Jan 1, 2024) | Approval Letter | Assyro This is a Complete Response Letter from the FDA to Eli Lilly and Company regarding their Biologics License Application (BLA) for lebrikizumab injection. The... approval letter jan assyro https://assyro.com/regulatory-intelligence/us/letters/approved/761367orig1s000otheractionltrs Approval Letter Other (Nov 13, 2025) | Approval Letter | Assyro This letter from the FDA outlines deficiencies in a Biologics License Application (BLA 761367) and provides specific requirements for resubmission. It covers... approval letter nov assyro https://assyro.com/tools/pdufa-calendar/2027/october October 2027 FDA PDUFA Calendar: Drug Approval Dates | Assyro Track October 2027 FDA PDUFA dates for NDA, BLA, ANDA, and IND decisions. Free drug approval tracker with source-linked deadlines, calendar views, and daily... drug approval october fda calendar dates https://assyro.com/blog/corrective-preventive-action-capa-guide CAPA Process: FDA Compliance Guide (Updated May 2026) | Assyro AI May 1, 2026 - Corrective and preventive action (CAPA) requirements under 21 CFR 820.100. Learn the 7-step CAPA process, root cause analysis, and FDA expectations. fda compliance capa process guide updated https://assyro.com/glossary/purple-book Purple Book (Purple Book) - Definition | Assyro AI FDA's database of biological products licensed under the Public Health Service Act, including originator biologics and biosimilars. Learn more about Purple... purple book definition assyro ai https://assyro.com/submissions/de-novo De Novo Submission Software | Assyro De Novo submission software for novel-device evidence planning, risk-control traceability, and classification-ready filing execution. de novo submission software assyro